Skip to main content
Top
Published in: Rheumatology International 4/2013

01-04-2013 | Original Article

The frequency of antibodies against cyclic citrullinated peptides and rheumatoid factor in healthy population: a field study of rheumatoid arthritis from northern turkey

Authors: Turker Tasliyurt, Bunyamin Kisacik, Suheyla Uzun Kaya, Beytullah Yildirim, Yavuz Pehlivan, Faruk Kutluturk, Huseyin Ozyurt, Semsettin Sahin, Ahmet Mesut Onat

Published in: Rheumatology International | Issue 4/2013

Login to get access

Abstract

Rheumatoid arthritis (RA) is a chronic, systemic and an autoimmune disease characterized by inflammation of the synovial membrane that affects approximately 1 % of the total world population. Rheumatoid factor (RF) is a widely used auto antibody in diagnosis of the RA and found positive in 50–80 % of the patients but with a lower specificity. On the other hand, anti-cyclic citrullinated peptide (anti-CCP) is the latest serological marker with a specificity around 98 %. This field survey was conducted in different regions to investigate the frequency of RF and anti-CCP and also frequency of RA in a northern province of Turkey. This study was conducted in 70 local areas (12 urban and 58 rural) in the province of Tokat, which is located in northern Turkey. The population of Tokat was reported to be 828,000 at the last census and about 530,000 individuals aged > 18years old. The study population of 941 subjects (462 male and 479 female; urban 501 and rural 440) was selected by random sampling method among 530,000 individuals. Of the 941 healthy controls assigned to the study, 479 of them were female (51 %) and 462 of them were males (49 %), and median age of all participants was 41 ± 17. Twenty-six subjects were RF positive (2.8 %), and 9 patients were anti-CCP positive (1 %). The presence of both RF and anti-CCP antibodies has also been shown in two patients (0.2 %). In conclusion, we demonstrated that the frequency of RA was 0.53 %, RF presence was 2.8 %, and anti-CCP presence was 1 % in total 941 healthy subjects enrolled into study.
Literature
1.
3.
go back to reference Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet 373(659):672 Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet 373(659):672
4.
go back to reference Schellekens GA, Visser H, de Jong BA et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRef Schellekens GA, Visser H, de Jong BA et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRef
5.
6.
go back to reference Lee AN, Beck CE, Hall M (2008) Rheumatoid factor and anti-CCP antibodies in rheumatoid arthritis: a review. Clin Lab Sci 21:15–18PubMed Lee AN, Beck CE, Hall M (2008) Rheumatoid factor and anti-CCP antibodies in rheumatoid arthritis: a review. Clin Lab Sci 21:15–18PubMed
7.
go back to reference Aletaha D, Neogi T, Silman AJ et al (2010) Rheumatoid arthritis classification criteria. Arthritis Rheum 62:2569–2581PubMedCrossRef Aletaha D, Neogi T, Silman AJ et al (2010) Rheumatoid arthritis classification criteria. Arthritis Rheum 62:2569–2581PubMedCrossRef
8.
go back to reference Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
9.
go back to reference Akar S, Birlik M, Guler O et al (2004) The prevalence of rheumatoid arthritis in an urban population of Izmir-Turkey. Clin Exp Rheumatol 22:416–420PubMed Akar S, Birlik M, Guler O et al (2004) The prevalence of rheumatoid arthritis in an urban population of Izmir-Turkey. Clin Exp Rheumatol 22:416–420PubMed
10.
go back to reference Kacar C, Gilgil E, Tuncer T et al (2005) Prevalence of rheumatoid arthritis in Antalya, Turkey. Clin Rheumatol 24:212–214PubMedCrossRef Kacar C, Gilgil E, Tuncer T et al (2005) Prevalence of rheumatoid arthritis in Antalya, Turkey. Clin Rheumatol 24:212–214PubMedCrossRef
11.
go back to reference Capkin E, Cakirbay H, Karkucak M et al (2010) Prevalence of rheumatoid arthritis in the eastern Black Sea region of Turkey. Int J Rheum Dis 13(4):380–384PubMedCrossRef Capkin E, Cakirbay H, Karkucak M et al (2010) Prevalence of rheumatoid arthritis in the eastern Black Sea region of Turkey. Int J Rheum Dis 13(4):380–384PubMedCrossRef
12.
go back to reference Cakır N, Pamuk ÖN, Derviş E et al (2012) The prevalences of some rheumatic diseases in western Turkey: Havsa study. Rheumatol Int 32(4):895–908 Cakır N, Pamuk ÖN, Derviş E et al (2012) The prevalences of some rheumatic diseases in western Turkey: Havsa study. Rheumatol Int 32(4):895–908
13.
go back to reference Van Venrooij WJ, Pruijn GJ (2000) Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res 2(4):249–251PubMedCrossRef Van Venrooij WJ, Pruijn GJ (2000) Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res 2(4):249–251PubMedCrossRef
14.
go back to reference Kakumanu P, Yamagata H, Sobel ES et al (2008) Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum 58(6):1576–1581PubMedCrossRef Kakumanu P, Yamagata H, Sobel ES et al (2008) Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum 58(6):1576–1581PubMedCrossRef
15.
go back to reference Kakumanu P, Sobel ES, Narain S et al (2009) Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol 36(12):2682–2690PubMedCrossRef Kakumanu P, Sobel ES, Narain S et al (2009) Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol 36(12):2682–2690PubMedCrossRef
16.
go back to reference Gottenberg JE, Mignot S, Nicaise-Rolland P et al (2005) Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren’s syndrome. Ann Rheum Dis 64(1):114–117PubMedCrossRef Gottenberg JE, Mignot S, Nicaise-Rolland P et al (2005) Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren’s syndrome. Ann Rheum Dis 64(1):114–117PubMedCrossRef
17.
go back to reference Ingegnoli F, Galbiati V, Zeni S et al (2007) Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol 26(4):510–514PubMedCrossRef Ingegnoli F, Galbiati V, Zeni S et al (2007) Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol 26(4):510–514PubMedCrossRef
18.
go back to reference Takasaki Y, Yamanaka K, Takasaki C et al (2004) Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol 14(5):367–375PubMedCrossRef Takasaki Y, Yamanaka K, Takasaki C et al (2004) Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol 14(5):367–375PubMedCrossRef
19.
go back to reference Li T, Bao J, Yin J et al (2011) The specificity of anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis from a large cohort study in the Chinese. Zhonghua Nei Ke Za Zhi. 50(2):99–101PubMed Li T, Bao J, Yin J et al (2011) The specificity of anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis from a large cohort study in the Chinese. Zhonghua Nei Ke Za Zhi. 50(2):99–101PubMed
20.
go back to reference Goeldner I, Skare TL, de Messias Reason IT et al (2010) Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in rheumatoid arthritis patients and relatives from Brazil. Rheumatology (Oxford) 49(8):1590–1593CrossRef Goeldner I, Skare TL, de Messias Reason IT et al (2010) Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in rheumatoid arthritis patients and relatives from Brazil. Rheumatology (Oxford) 49(8):1590–1593CrossRef
21.
go back to reference Avouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65(7):845–851PubMedCrossRef Avouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65(7):845–851PubMedCrossRef
22.
go back to reference Lipsky PE (2005) Rheumatoid arthritis. In: Braunwald E (ed) Harrison’s 16th edition Principles of İnternal Medicine. Mc Graw Hill, New York, pp 1968–1976 Lipsky PE (2005) Rheumatoid arthritis. In: Braunwald E (ed) Harrison’s 16th edition Principles of İnternal Medicine. Mc Graw Hill, New York, pp 1968–1976
23.
go back to reference Klareskog L, Stolt P, Lundberg K et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:38–46PubMedCrossRef Klareskog L, Stolt P, Lundberg K et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:38–46PubMedCrossRef
Metadata
Title
The frequency of antibodies against cyclic citrullinated peptides and rheumatoid factor in healthy population: a field study of rheumatoid arthritis from northern turkey
Authors
Turker Tasliyurt
Bunyamin Kisacik
Suheyla Uzun Kaya
Beytullah Yildirim
Yavuz Pehlivan
Faruk Kutluturk
Huseyin Ozyurt
Semsettin Sahin
Ahmet Mesut Onat
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2458-5

Other articles of this Issue 4/2013

Rheumatology International 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.